 According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically “for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV).Facial lipoatrophy is a condition in which people lose fat in their faces, especially in their cheeks and around their eyes and temples.People with HIV who take anti-HIV drugs may develop lipoatrophy.